nach oben

Current Infectious Disease Reports

Erschienen in:

01.02.2012 | Intra-abdominal Infections, Hepatitis, and Gastroenteritis (DA Bobak, Section Editor)

Update on Cytomegalovirus Infections of the Gastrointestinal System in Solid Organ Transplant Recipients

verfasst von: Tracy L. Lemonovich, Richard R. Watkins

Erschienen in: Current Infectious Disease Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Cytomegalovirus (CMV) infection of the gastrointestinal tract is the most common manifestation of tissue-invasive CMV disease, and is a significant cause of morbidity and mortality in the solid organ transplantation (SOT) recipient. In addition to the direct effects of the infection, its indirect effects on allograft function, risk for other opportunistic infections, and mortality are significant in this population. The most common clinical syndromes are esophagitis, colitis, and hepatitis; however, infection can occur anywhere in the gastrointestinal tract. Diagnosis is usually by histopathology or viral culture of tissue specimens; molecular assays also often have a role. Antivirals are the cornerstone of therapy for gastrointestinal tract CMV disease and complications such as recurrent infection and antiviral resistance are not uncommon. Prevention with antiviral prophylaxis or preemptive therapy is important. This review summarizes recent data regarding the clinical manifestations, diagnosis, treatment, and prevention of gastrointestinal tract CMV infection in the SOT population.

• Eid AJ, Razonable RR: New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010, 70:965–981. Excellent review of recent management issues in CMV infection after SOT PubMedCrossRef

Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med. 2010;267:483–501.PubMedCrossRef

Kotton CN. Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol. 2010;6:711–21.PubMedCrossRef

Ozdemir FN, Akgul A, Altunoglu A, et al. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. Transplant Proc. 2007;39:990–2.PubMedCrossRef

Rodrigo E, Fernandez-Fresnedo G, Valero R, et al. New-onset diabetes after kidney transplantation: risk factors. J Am Soc Nephrol. 2006;17 Suppl 3:S291–5.PubMedCrossRef

Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006;82(2 Suppl):S15–7.PubMedCrossRef

Bobak DA. Gastrointestinal infections caused by cytomegalovirus. Curr Infect Dis Rep. 2003;5:101–7.PubMedCrossRef

Trappe R, Pohl H, Forberger A, et al. Acute esophageal necrosis (black esophagus) in the renal transplant recipient: manifestation of primary cytomegalovirus infection. Transpl Infect Dis. 2007;9:42–5.PubMedCrossRef

Harada N, Shimada M, Suehiro T, et al. Unusual endoscopic findings of CMV esophagitis after liver transplantation. Hepatogastroenterology. 2005;52:1236–9.PubMed

10.

Li W, Fan H, Yiping L. Postural epigastric pain as a sign of cytomegalovirus gastritis in renal transplant recipients: a case-based review. Transplant Proc. 2009;41:3956–8.PubMedCrossRef

11.

Llado L, Castellote J, Fabregat J, et al. Antral mass due to cytomegalovirus infection requiring gastrectomy in a liver transplant recipient. Transpl Infect Dis. 2008;10:354–7.PubMedCrossRef

12.

Talmon GA. Histologic features of cytomegalovirus enteritis in small bowel allografts. Transplant Proc. 2010;42:2671–5.PubMedCrossRef

13.

Petrilsi E, Chiereghin A, Gabrielli L, et al. Early and late virologic monitoring of cytomegalovirus, Epstein-Barr virus, and human herpes virus 6 infections in small bowel/multivisceral transplant recipients. Transplant Proc. 2010;42:74–8.CrossRef

14.

Navaneethan U, Venkatesh PG, Wang J. Cytomegalovirus ileitis in a patient after liver transplantation- differentiating from de novo IBD. J Crohns Colitis. 2011;5:354–9.PubMedCrossRef

15.

Dahman M, Krell R, Brayman K, et al. Simultaneous Clostridium difficile-associated colitis and late-onset intestinal cytomegalovirus disease in a renal transplant recipient. Ann Transplant. 2010;15:72–6.PubMed

16.

Veroux M, Puzzo L, Corona D, et al. Cytomegalovirus and Clostridium difficile ischemic colitis in a renal transplant recipient: a lethal complication of anti-rejection therapy? Urol Int. 2007;79:177–9.PubMedCrossRef

17.

Hampton DD, Poleski MH, Onken JE. Inflammatory bowel disease following solid organ transplantation. Clin Immunol. 2008;128:287–93.PubMedCrossRef

18.

Verdonk RC, Haagsma EB, Van Den Berg AP, et al. Inflammatory bowel disease after liver transplantation: a role for cytomegalovirus infection. Scand J Gastroenterol. 2006;41:205–11.PubMedCrossRef

19.

Lee SO, Razonable RR. Current concepts on cytomegalovirus infection after liver transplantation. World J Hepatol. 2010;2:325–36.PubMedCrossRef

20.

Demetris AJ. Evolution of hepatitis C in liver allografts. Liver Transpl. 2009;15 Suppl 2:S35–41.PubMedCrossRef

21.

Ramirez S, Perez-Del-Pulgar S, Forns X. Virology and pathogenesis of hepatitis C recurrence. Liver Transpl. 2008;14 Suppl 2:S27–35.PubMedCrossRef

22.

Razonable RR, Burak KW, van Cruijsen H, et al. The pathogenesis of hepatitis C virus is influenced by cytomegalovirus. Clin Infect Dis. 2002;35:974–81.PubMedCrossRef

23.

Drage M, Reid A, Callaghan CJ, et al. Acute cytomegalovirus cholecystitis following renal transplantation. Am J Transplant. 2009;9:1249–52.PubMedCrossRef

24.

Baroco AL, Oldfield EC. Gastrointestinal cytomegalovirus disease in the immunocompromised patient. Curr Gastroenterol Rep. 2008;10:409–16.PubMedCrossRef

25.

Kamalkumar BS, Agarwal SK, Garg P, et al. Acute pancreatitis with CMV papillitis and cholangiopathy in a renal transplant recipient. Clin Exp Nephrol. 2009;13:389–91.PubMedCrossRef

26.

Klassen DK, Drachenberg CB, Papadimitriou JC, et al. CMV allograft pancreatitis: diagnosis, treatment, and histological features. Transplantation. 2000;69:1968–71.PubMedCrossRef

27.

••Kotton CN, Kumar D, Caliendo AM, et al.: International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89:779–795. Recent international consensus guidelines with extensive review of the literature by international transplant experts on management of CMV in SOT PubMedCrossRef

28.

Halme L, Lempinen M, Arola J, et al. High frequency of gastroduodenal cytomegalovirus infection in liver transplant patients. APMIS. 2008;116:99–106.PubMedCrossRef

29.

•Grim SA, Pereira E, Guzman G, et al.: CMV PCR as a diagnostic tool for CMV gastrointestinal disease after solid organ transplantation. Transplantation 2010, 90:799–801. Overview of recent available data on use of molecular assays for diagnosis of gastrointestinal tract disease in SOT PubMedCrossRef

30.

Eid AJ, Arthurs SK, Deziel PJ, et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162–70.PubMedCrossRef

31.

Halme L, Hockerstedt K, Samela K, et al. CMV infection detected in the upper gastrointestinal tract after liver transplantation. Transpl Int. 1998;11 Suppl 1:S242–4.PubMed

32.

Jang EY, Park SY, Lee EJ, et al. Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. Clin Infect Dis. 2009;48:e121–4.PubMedCrossRef

33.

Fica A, Cervera C, Perez N, et al. Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis. 2007;9:203–10.PubMedCrossRef

34.

Ganzenmueller T, Henke-Gendo C, Schlue J, et al. Quantification of cytomegalovirus DNA levels in intestinal biopsies as a diagnostic tool for CMV intestinal disease. J Clin Virol. 2009;46:254–8.PubMedCrossRef

35.

Muir SW, Murray J, Farquharson MA, et al. Detection of cytomegalovirus in upper gastrointestinal biopsies from heart transplant recipients: comparison of light microscopy, immunocytochemistry, in situ hybridisation, and nested PCR. J Clin Pathol. 1998;51:807–11.PubMedCrossRef

36.

Brainard JA, Greenson JK, Vesy CJ, et al. Detection of cytomegalovirus in liver transplant biopsies. A comparison of light microscopy, immunohistochemistry, duplex PCR and nested PCR. Transplantation. 1994;57:1753–7.PubMed

37.

Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S78–86.PubMedCrossRef

38.

Asberg A, Humar A, Rollaq H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2007;7:2106–13.PubMedCrossRef

39.

•Eid AJ, Arthurs SK, Deziel PJ et al.: Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients. Am J Transpl 2010, 10:157–161. Study of clinical risk factors for relapse of gastrointestinal CMV disease in SOT recipients CrossRef

40.

Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 2002;35:866–72.PubMedCrossRef

41.

Li F, Kenyon KW, Kirby KA, et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis. 2007;45:439–47.PubMedCrossRef

42.

Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645–9.PubMedCrossRef

43.

Bhorade SM, Lurain NS, Jordan A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J Heart Lung Transplant. 2002;21:1274–82.PubMedCrossRef

44.

Limaye AP, Raghu G, Koelle DM, et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis. 2002;185:20–7.PubMedCrossRef

45.

Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis. 2004;189:1615–8.PubMedCrossRef

46.

•Myhre HA, Haug Dorenberg D, Kristiansen KI, et al.: Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients. Transplantation 2011, 92:217–223. Largest outcome study to date of ganciclovir-resistant CMV infections in SOT recipients PubMedCrossRef

47.

Boivin G, Goyette N, Rollaq H, et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther. 2009;14:697–704.PubMed

48.

Hantz S, Garnier-Geoffroy F, Mazeron MC, et al. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65:2628–40.PubMedCrossRef

49.

•Drew WL: Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis 2010, 50:733–736. Concise review of CMV resistance testing PubMedCrossRef

50.

West P, Schmiedeskamp M, Neeley H, et al. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL 97 mutation. Transpl Infect Dis. 2008;10:129–32.PubMedCrossRef

51.

Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12:489–96.PubMedCrossRef

52.

Snydman DR. Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection. Transplantation. 2010;90:362–3.PubMedCrossRef

53.

Shapira MY, Resnick IB, Chou S, et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis. 2008;46:1455–7.PubMedCrossRef

54.

Dropulic LK, Cohen JI. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin Pharmacol Ther. 2010;88:610–9.PubMedCrossRef

55.

Avery RK. Update in the management of ganciclovir-resistant cytomegalovirus infection. Curr Opin Infect Dis. 2008;21:433–7.PubMedCrossRef

56.

Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant. 2008;8:975–83.PubMedCrossRef

57.

Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870–80.PubMed

58.

Reischig T, Jindra P, Hes O, et al. Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant. 2008;8:69–77.PubMed

59.

•Humar A, Lebranchu Y, Vincenti F, et al.: The efficacy and safety of 200 days of valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10:1228–1237. Important efficacy study of extended duration valganciclovir prophylaxis in D+/R- kidney transplant recipients in decreasing incidence of CMV disease PubMedCrossRef

60.

Arthurs SK, Eid AJ, Pedersen RA, et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis. 2008;46:840–6.PubMedCrossRef

61.

Boudreault AA, Xie H, Rakita RM, et al. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis. Transpl Infect Dis. 2011;13:244–9.PubMedCrossRef

62.

Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al. Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant. 2007;26:1019–24.PubMedCrossRef

63.

Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001;184:1461–4.PubMedCrossRef

64.

•Humar A, Limaye AP, Blumberg EA, et al.: Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010, 90:1427–1431. Follow-up 2 year results of efficacy study of extended duration valganciclovir prophylaxis in D+/R- kidney transplant recipients showing long-term reduction in CMV disease PubMedCrossRef

65.

Walker JK, Scholz LM, Scheetz MN, et al. Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction. Transplantation. 2007;83:874–82.PubMedCrossRef

66.

Razonable RR, van Cruijsen H, Brown RA, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis. 2003;187:1801–8.PubMedCrossRef

67.

Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22:76–98.PubMedCrossRef

68.

Sund F, Lidehall AK, Claesson K, et al. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study. Clin Transplant. 2010;24:401–9.PubMedCrossRef

69.

Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation. 1994;58:1176–8.PubMed

70.

•Griffiths PD, Stanton A, McCarrell E, et al.: Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256–1263. First randomized trial of a CMV vaccine given pre-SOT showing reduction in duration of CMV viremia and ganciclovir use post-transplant in D+/R- vaccinees PubMedCrossRef

Titel: Update on Cytomegalovirus Infections of the Gastrointestinal System in Solid Organ Transplant Recipients
verfasst von: Tracy L. Lemonovich
Richard R. Watkins
Publikationsdatum: 01.02.2012
Verlag: Current Science Inc.
Erschienen in: Current Infectious Disease Reports / Ausgabe 1/2012
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-011-0224-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs

Current Concept in the Pathophysiology of Hepatitis Delta Infection

Molecular Diagnosis of Diarrhea: Current Status and Future Potential

The Role of Innate Immunity in the Host Defense Against Intestinal Bacterial Pathogens

Diagnosis, Treatment, and Prevention of Anal Cancer